Ferring Pharmaceuticals

Wednesday , September 15, 2010
13h00 – 14h30
Room 114 – Level 1

Lunch and drinks are courtesy of Ferring

Gonadotrophin -releasing hormone (GnRH) receptor blockade :
the new approach to prostate cancer management

13:00–13:05 Welcome and objectives
Heather Payne, University College Hospital, London, UK (Chair)

13:05–13:25 Clinical development of a new GnRH Blocker
Bo-Eric Persson, Ferring Pharmaceuticals, St-Prex, Switzerland

13:25–13:45 Importance of testosterone suppression in ADT
Juan Morote, Vall d’Hebron General Hospital, Barcelona, Spain

13:45–14:05 Which patients will benefit from GnRH Blocker therapy?
Thomas E Keane, Medical University of South Carolina, Charleston, USA

14:05–14:25 Neoadjuvant/adjuvant hormonal treatment
Heather Payne, University College Hospital, London, UK

14:25–14:30 Conclusions
Heather Payne, University College Hospital, London, UK (Chair)